CAVEAT: A randomised, double-blind, parallel group evaluation of cerivastatin 0.4 mg and 0.8 mg compared to atorvastatin 10 mg and 20 mg once daily in patients with combined (type IIb) dyslipidaemia

British Journal of Cardiology

Volumn 7, Issue 12, 2000, Pages 780-786

  Ma, P ^a   Hegele, R ^a   Yale, J F ^a   Schwartz, B ^a  

^a Heart Health Institute   (Canada)

Author keywords

Atorvastatin; Cerivastatin; Combined (type IIb) dyslipidaemia; HMG CoA reductase inhibitors; Hypercholesterolaemia; Hypertriglyceridaemia

Indexed keywords

ATORVASTATIN; CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034533427     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Factors associated with lipoprotein cholesterol levels. The Framingham study
2. Lipid-lowering therapy for the primary prevention of coronary heart disease
3. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group
4. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
5. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol And Recurrent Events trial investigators
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
7. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
8. Hypertriglyceridemia as a cardiovascular risk factor
9. Comparison of statins in hypertriglyceridemia
10. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
11. Safety and efficacy of cerivastatin 0.8 mg daily for 8 weeks: The pivotal placebo-controlled clinical trial
12. A pooled efficacy analysis of cerivastatin in the treatment of primary hypercholesterolemia
13. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias
14. IMS+ National Prescription Audit
15. The emergence of triglycerides as a significant independent risk factor in coronary artery disease
16. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: The pivotal placebo-controlled clinical trial
17. Improved NCEP-Goal Attainment with Cerivastatin: Outcome of Mandated Department of Defense Statin Conversion
18. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
19. Plasma triglyceride and coronary heart disease